Novavax Statement on Completion of the National Research Council of Canada Biologics Manufacturing Centre
The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry announced today that construction of the new Biologics Manufacturing Centre (BMC) at the National Research Council of Canada's (NRC)’s Royalmount location in Montréal, Québec has been completed.
The partnership will enable the first manufacturing capabilities in Canada for a COVID-19 vaccine once the facility and NVX-CoV2373, Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate, receive the required Health Canada approvals. Novavax and the NRC are working closely together on technology transfer to establish the step-by-step process of producing NVX-CoV2373 at the BMC.
Large-scale GMP production is expected to begin once the facility has received Health Canada regulatory approval. We look forward to a close collaboration between the two organizations to facilitate production of the Novavax vaccine in Canada as quickly as possible.
In February 2021, Novavax signed a memorandum of understanding (MOU) with the Government of Canada to pursue options to produce its COVID-19 vaccine candidate at the BMC. In March 2021, Novavax signed a collaboration agreement with the NRC to enable technology transfer to begin in early April. To learn more, read NRC’s press release here.